TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06788288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Chair session
Description: The intervention is composed of a full-body relaxation massage offered by an automatic electric massage chair. The intervention will last for 3 months while the participant will change between massage and washout periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Chair session
Description: The intervention is composed of a full-body relaxation massage offered by an automatic electric massage chair. The intervention will last for 3 months while the participant will change between massage and washout periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout period
Description: During this phase, participants will spend on month without any intervention (massage) accounting for a washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout period
Description: During this phase, participants will spend on month without any intervention (massage) accounting for a washout period.
Study: NCT06788405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand hygiene theoretical training with a hand hygiene virtual reality simulation application
Description: After giving 360 hours of hand hygiene theoretical training to the participants in the experimental group, a hand hygiene virtual reality simulation application will be performed.
Study: NCT05402163

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous DBS
Description: aDBS vs cDBS
Study: NCT06788405

Intervention type: OTHER
Group type: OTHER
Intervention: hand hygiene theoretical training
Description: Participants in the control group will receive only 360 hours of hand hygiene theoretical training. Participants in this group will not be given hand hygiene virtual reality simulation application.
Study: NCT06786598

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cholesterol
Description: Qimica/kit
Study: NCT05609630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet or Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet or Oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Subcutaneous injection or Intravenous infusion
Study: NCT05419466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
Description: dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
Study: NCT04821102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline, 1 time injection under ultrasonic guided
Study: NCT05221632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated transcranial magnetic stimulation with real coil
Description: The stimulation mode of TMS is accelerated continue theta-burst stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation with real coil
Description: The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation with sham coil
Description: The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
Study: NCT05340712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: new infant formula
Description: New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula
Description: Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
Study: NCT05998850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Support with Resources
Description: 6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
Study: NCT06372171

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Satge 1
Description: General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Stage 2
Description: General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
Study: NCT05872386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buprenorphine uptake/retention via Telehealth
Description: Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
Study: NCT05980416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO-3021
Description: Anti-Claudin 18.2 antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO-3021
Description: Anti-Claudin 18.2 antibody drug conjugate
Study: NCT05957393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantity of vaccination recommendations
Description: The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantity of vaccination recommendations
Description: The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of vaccination recommendations
Description: The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of vaccination recommendations
Description: The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
Study: NCT05666934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Storybook
Description: The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
Study: NCT05878886

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Emergency Food Product
Description: Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Emergency Food Product
Description: Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
Study: NCT05010200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGV-001
Description: personalized genomic peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGV-001
Description: personalized genomic peptide vaccine
Study: NCT06501885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethnodrama Intervention
Description: The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
Study: NCT06376162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV infusion
Study: NCT05010200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGV-001
Description: personalized genomic peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: immune modulator
Study: NCT06221150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral two level serratus anterior block
Description: A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Intraoperative opioids without regional block
Study: NCT05272878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IRBESARTAN, tablet, 150 mg
Description: IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, tablet, 150 mg
Description: Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
Study: NCT06208462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 1200mg，i.v. , q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg,qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg/m2，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2，q3w
Study: NCT06182995

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care post-Intensive Care Unit (ICU)
Description: routine clinic visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipating Decline and Providing Therapy (ADAPT)
Description: routine validated cognitive screen for high-risk older adults at 6 weeks and 6 months post-ICU discharge
Study: NCT06301919

Intervention type: OTHER
Intervention: Clinical data
Description: Collecting data from the medical record.

Intervention type: OTHER
Intervention: Imaging data
Description: Collecting data from the medical record.

Intervention type: OTHER
Intervention: Biological data
Description: Collecting data from the medical record.
Study: NCT05023928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor antigen-sensitized DC vaccine
Description: subcutaneous administration
Study: NCT05637320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems
Description: The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
Study: NCT06634368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital GamePlan4Care
Description: The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
Study: NCT04305431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Intervention
Description: 90-minute culinary education sessions.
Study: NCT05837936

Intervention type: OTHER
Intervention: Total intravenous anesthesia (TIVA)
Description: TIVA anesthetic -no inhalational gases for surgery
Study: NCT06359470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning technique
Description: First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation.
Study: NCT06358365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AquaPass System
Description: The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
Study: NCT06175299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Promotion With Person-centered Technology (APPT) System with Social Functions
Description: The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
Study: NCT05010200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: immune modulator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: immune modulator
Study: NCT05240300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BX005-A
Description: phage gel
Study: NCT05837936

Intervention type: OTHER
Intervention: Sevoflurane initiated intravenous anesthesia (SIIVA)
Description: SIIVA - sevoflurane anesthetic gases for surgery
Study: NCT06014086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-762
Description: PH-762 is a potent RNAi molecule targeting PD-1.
Study: NCT05240300

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle gel
Study: NCT05323032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal electroretinogram (mf-ERG) by electroretinogram device
Description: Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
Study: NCT05891132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml of lidocaine 2%
Description: 10 ml of lidocaine 2% for perineal infiltration at the time of crowning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine prilocaine cream 15gm
Description: Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
Study: NCT06459947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft procedure
Description: The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft procedure
Description: The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft procedure
Description: The palatal area is anesthetized using local anesthesia. The free gingival graft (FGG) is taken from the donor site with a scalpel.
Study: NCT06548412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV
Study: NCT06364852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY007
Description: FC and LY007 infusion
Study: NCT05719519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial periodontal therapy and 3D intraoral scanning
Description: Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial periodontal therapy and 3D intraoral scanning
Description: Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
Study: NCT05010200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: soluble recombinant human protein to work on stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: soluble recombinant human protein to work on stem cell
Study: NCT05558358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation
Description: 6 months of active stimulation -- \> 6 months of sham stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation
Description: 6 months of sham stimulation -- \> 6 months of active stimulation
Study: NCT06368505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided PRP injection
Description: whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided hydrodissection
Description: 5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
Study: NCT05664659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin + misoprostol
Description: 600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 100 micrograms carbetocin
Study: NCT06548412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009
Description: Given by IV